Developing novel humanized monoclonal antibodies with ultra-long CDRs inspired by nature to target the gp120 of HIV
Immunoglobulin G (IgG) antibodies are essential components of our immune system. IgGs recognize and bind antigens with their hypervariable complementarity-determining regions (CDRs). Human IgGs have only relatively short CDRs, which limits their ability to recognize some antigens like the human immunodeficiency virus (HIV). Interestingly, bovine antibodies can have exceptionally long and complex CDRs, allowing them to bind HIV proteins like the gp120 with high affinity. Inspired by the nature of the bovine antibodies, our goal is to graft long CDRs in human antibodies and to develop stable humanized IgG antibodies with ultra-long CDRs that bind to the gp120 of HIV. These new humanized IgGs will offer possibilities for the prevention and treatment of AIDS.
Here you can get further information.